BMRN
$BMRN
BioMarin Pharmaceutical Inc.
Rare disease biotech company with gene therapy and enzyme replacement treatments.
HealthcareSubscribers
0
Tracking this ticker
Next Report
Sun, Mar 22
Weekly updates
Latest Report
BMRN: Growth Catalysts and FDA Wins
BioMarin delivered 13% revenue growth in 2025, secured an adolescent approval for PALYNZIQ, and announced pipeline and partnership catalysts. Analysts are broadly bullish, but Q4 2025 execution and regulatory risk merit close monitoring.
Mar 16, 2026